Follow
D J Leishman
D J Leishman
Vice President, Translational and Quantitative Toxicology (TQT)
Verified email at safetypharmacologysource.com
Title
Cited by
Cited by
Year
Structural determinants of HERG channel block by clofilium and ibutilide
M Perry, MJ de Groot, R Helliwell, D Leishman, M Tristani-Firouzi, ...
Molecular pharmacology 66 (2), 240-249, 2004
1852004
Towards a drug concentration effect relationship for QT prolongation and torsades de pointes.
R Webster, D Leishman, D Walker
Current opinion in drug discovery & development 5 (1), 116-126, 2002
1422002
Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin
AJ Alexandrou, RS Duncan, A Sullivan, JC Hancox, DJ Leishman, ...
British journal of pharmacology 147 (8), 905-916, 2006
1252006
Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics
HM Vargas, AS Bass, A Breidenbach, HS Feldman, GA Gintant, ...
Journal of pharmacological and toxicological methods 58 (2), 72-76, 2008
1022008
Drug binding interactions in the inner cavity of HERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs
M Perry, PJ Stansfeld, J Leaney, C Wood, MJ De Groot, D Leishman, ...
Molecular pharmacology 69 (2), 509-519, 2006
1002006
Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 C: Cisapride versus dofetilide
JT Milnes, HJ Witchel, JL Leaney, DJ Leishman, JC Hancox
Journal of pharmacological and toxicological methods 61 (2), 178-191, 2010
972010
Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: current recommendations from the Safety Pharmacology Society
DJ Leishman, TW Beck, N Dybdal, DJ Gallacher, BD Guth, M Holbrook, ...
Journal of Pharmacological and Toxicological Methods 65 (3), 93-101, 2012
952012
Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc
DA Price, D Armour, M de Groot, D Leishman, C Napier, M Perros, ...
Bioorganic & medicinal chemistry letters 16 (17), 4633-4637, 2006
892006
A framework to assess the translation of safety pharmacology data to humans
JP Valentin, R Bialecki, L Ewart, T Hammond, D Leishmann, S Lindgren, ...
Journal of Pharmacological and Toxicological Methods 60 (2), 152-158, 2009
812009
Identification of a low molecular mass (14.2 kDa) α-tocopherol-binding protein in the cytosol of rat liver and heart
AK Duttaroy, DJ Leishman, MJ Gordon, FM Campbell, GG Duthie
Biochemical and biophysical research communications 196 (3), 1108-1112, 1993
791993
A pharmacokinetic‐pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether‐a‐go‐go‐related gene current inhibition data
DM Jonker, LA Kenna, D Leishman, R Wallis, PA Milligan, EN Jonsson
Clinical pharmacology & therapeutics 77 (6), 572-582, 2005
772005
General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy
Z Li, GR Mirams, T Yoshinaga, BJ Ridder, X Han, JE Chen, ...
Clinical Pharmacology & Therapeutics 107 (1), 102-111, 2020
702020
The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative
L Ewart, M Aylott, M Deurinck, M Engwall, DJ Gallacher, H Geys, P Jarvis, ...
Toxicological Sciences 142 (2), 427-435, 2014
702014
Cardiac Safety Research Consortium: can the thorough QT/QTc study be replaced by early QT assessment in routine clinical pharmacology studies? Scientific update and a research …
B Darpo, C Garnett, CT Benson, J Keirns, D Leishman, M Malik, ...
American heart journal 168 (3), 262-272, 2014
702014
Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin
RS Duncan, MJ McPate, JM Ridley, Z Gao, AF James, DJ Leishman, ...
Biochemical pharmacology 74 (3), 425-437, 2007
682007
The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment
AA Fossa, MJ DePasquale, DL Raunig, MJ Avery, DJ Leishman
Journal of Pharmacology and Experimental Therapeutics 302 (2), 828-833, 2002
622002
Purification and partial characterisation of an α-tocopherol-binding protein from rabbit heart cytosol
AK Dutta-Roy, MJ Gordon, DJ Leishman, BJ Paterson, GG Duthie, ...
Cellular Fatty Acid-Binding Proteins II: Proceedings of the 2nd …, 1993
561993
hERG K+ channel blockade by the antipsychotic drug thioridazine: An obligatory role for the S6 helix residue F656
JT Milnes, HJ Witchel, JL Leaney, DJ Leishman, JC Hancox
Biochemical and biophysical research communications 351 (1), 273-280, 2006
542006
Time for a fully integrated nonclinical–clinical risk assessment to streamline QT prolongation liability determinations: A pharma industry perspective
HM Vargas, MG Rolf, TA Wisialowski, W Achanzar, A Bahinski, A Bass, ...
Clinical Pharmacology & Therapeutics 109 (2), 310-318, 2021
522021
Erythromycin block of the HERG K+ channel: accessibility to F656 and Y652
RS Duncan, JM Ridley, CE Dempsey, DJ Leishman, JL Leaney, ...
Biochemical and biophysical research communications 341 (2), 500-506, 2006
502006
The system can't perform the operation now. Try again later.
Articles 1–20